This is a groundbreaking article, as it safely increases the population who do not need to undergo chemotherapy, even by conventional guidelines. To reiterate what I have said in the past, conventional chemotherapy dosing probably adds the most benefit in the adjuvant setting, as opposed to metastatic disease, where it improves survival marginally.
Having said that, of course we do not want to use it in the adjuvant setting, if it does not improve progression-free or overall survival.
Bottom line: In the 50-75 year old age group, with ER+, Her-2 neg cancer and negative nodes, with an Oncotype Recurrence Score between 11 and 25, chemotherapy is NOT indicated. In women younger than 50, with Oncotype Recurrence Scores between 16 and 25, outcomes were only SLIGHTLY better in the chemotherapy group, so patients need to take that into consideration.
healthyliving April 9th, 2019
Posted In: cancer care
Tags: breast cancer, cancer, chemo, chemotherapy
